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Introduction: Congenital central hypoventilation syndrome is an autosomal dominant disorder that classically
presents as sudden death in infancy secondary to central hypoventilation. Most cases are caused by polyalanine
repeat mutations in the paired-like homeobox 2B gene, PHOX2B. More severe disease is typically associated with
nonpolyalanine repeat mutations. We report the case of a family with nonpolyalanine repeat mutations that
uncharacteristically has many individuals who were mildly symptomatic and only diagnosed after genetic testing.
We highlight the highly variable clinical presentation of this condition and the need for clinicians to remain vigilant.
Case presentation: We identified 10 individuals in a large extended Caucasian family of German and Austrian
background with congenital central hypoventilation syndrome.
Case 1: A 16-year old male proband presented for reproductive counseling. He had a previous history of apneic
spells and Hirschsprung disease in the neonatal period. A PHOX2B nonpolyalanine repeat mutation was identified in
the proband and used to screen his extended family.
Cases 2 to 10: Several mildly symptomatic family members (males aged 5, 13, 42 and 80 years; females aged 28, 44,
46 and 48 years) spanning four generations were identified after genetic screening. A newborn boy from this family
was also recently diagnosed with Hirschsprung disease and went on to have an abnormal sleep study.
Conclusions: In this report, we highlight the significant phenotypic variability of congenital central hypoventilation
syndrome, previously thought to be a rare genetic condition. Given the extreme clinical variability, it is possible that
the prevalence of congenital central hypoventilation syndrome in the general population is much higher than
previous estimates. This is of major importance to all clinicians who will need to maintain a high index of suspicion
for this not so rare and highly clinically variable genetic condition that spans all ages. As the familial mutation has
been identified, presymptomatic and prenatal diagnostic testing are available options for family members.Introduction
Congenital central hypoventilation syndrome (CCHS),
an autosomal dominant disorder that classically presents
as sudden death in infancy secondary to central hypo-
ventilation, was first reported in the 1970s [1-4]. The
molecular basis of CCHS was identified in 2009 and
attributed to mutations in the paired-like homeobox 2B
gene, PHOX2B. Two types of mutations have been
described: polyalanine repeat mutations (PARMs), which
are frequent, have a variable clinical presentation, and
disease severity correlates with allele size; and nonpoly-* Correspondence: edmond.lemire@saskatoonhealthregion.ca
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reproduction in any medium, provided the oralanine repeat mutations (NPARMS) that are usually as-
sociated with a more severe presentation including
Hirschsprung disease (HSCR) and an increased tumor
risk [1,3]. Milder forms of CCHS have been also de-
scribed and are due to smaller PARMs [1-6].
We report on a family in which the 16-year old male
proband presented with a previous history of HSCR and
apnea (also known as Haddad syndrome) in the neonatal
period. Genetic testing identified a PHOX2B NPARM,
which is typical for severe CCHS. Many adult family
members were only identified after genetic screening
and found to be mildly symptomatic. In this report, we
highlight the extreme clinical variability of CCHS and
the need for all clinicians to remain vigilant.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Bygarski et al. Journal of Medical Case Reports 2013, 7:117 Page 2 of 5
http://www.jmedicalcasereports.com/content/7/1/117Case presentation
Case 1 (III-3)
The proband (III-3), a 16-year-old Caucasian adolescent
of German and Austrian background, was referred for
reproductive counseling for HSCR (Figure 1). He was
born at term and transferred to a neonatal intensive care
unit because of hyperbilirubinemia, where he developed
central apneic spells with bradycardia and desaturations.
He was eventually discharged home on caffeine. At age
three weeks, he was readmitted because of abdominal
distension, vomiting and dehydration. Radiographic find-
ings were consistent with HSCR. He underwent a partial
colectomy and colostomy during this admission followed
by an endorectal pull-through at age 12 months. He was
hospitalized three times by eight years of age for recur-
rent episodes of abdominal pain and distension. He has
otherwise been healthy and his physical examination was
unremarkable. Mutation analysis found no mutations in
the RET gene. Targeted mutation analysis did not
detect a polyalanine repeat expansion in the PHOX2B
gene; however a novel frameshift mutation in exon 2
(c.391delC) associated with CCHS was identified. Our
patient was referred to Cardiology, Ophthalmology and
Respirology for assessment and management. His car-
diac assessment was normal; there were minor pupillary
abnormalities that did not require intervention. He had
a normal pulmonary function test and was scheduled for
an overnight sleep study, but failed to attend.Figure 1 Partial pedigree of the family with congenital central
hypoventilation syndrome. Squares indicate males and circles
indicate females. Filled symbols identify individuals with confirmed
and/or reported signs and symptoms of congenital central
hypoventilation syndrome. The proband is indicated by the arrow.
Confirmed PHOX2B mutation carriers are identified by an asterisk. A
dagger denotes that the individual was not assessed.Case 2 (II-5)
The proband’s 42-year-old father (II-5) was found to
carry the identical PHOX2B mutation. A review of his
medical history confirmed that he had unexplained
episodes of diaphoresis and pupils that dilated poorly
with atropine. A respiratory assessment found him to
have a low resting oxygen saturation level (91%) and
mild obstructive sleep apnea requiring nocturnal con-
tinuous positive airway pressure (CPAP).Case 3 (III-4)
The proband’s healthy 13-year-old brother had a remark-
able neonatal history as a term baby with an admission
to a neonatal intensive care unit for stridulous respira-
tions and desaturations (O2 levels down to 60% to 70%)
requiring supplementary oxygen. He was managed for
possible necrotizing enterocolitis, a rare entity in term
infants, with HSCR also under consideration in the dif-
ferential diagnosis.Case 4 (I-1)
The proband’s 80-year-old paternal grandfather was on
CPAP for severe obstructive sleep apnea and had had a
cardiac arrest in 2007. He had a reported history of
daily laxative use for chronic constipation and sluggish
pupillary responses to atropine.Case 5 (II-4)
A 44-year-old paternal aunt had a childhood history of
recurrent bronchitis and photophobia. Interestingly, she
was found to have unexplained low resting oxygen satur-
ation levels during a hospital admission for a cholecyst-
ectomy at age 25. She is now on CPAP for severe
obstructive sleep apnea and has shown signs of pulmon-
ary hypertension.Case 6 (II-3)
A 46-year-old paternal aunt has small pupils that react
sluggishly to light, sleep apnea and occasional episodes
of diaphoresis.Case 7 (III-2)
The 28-year old daughter of II-3, a paternal first cousin
to the proband (III-3), had a history of recurrent abdom-
inal pains and chronic constipation as a child.Case 8 (IV-1)
The newborn son of the III-2 was recently diagnosed
with HSCR and went on to have an abnormal sleep
study. He is being managed by noninvasive ventilation
and is undergoing screening for neural crest tumors.
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A 48-year-old paternal aunt reportedly has tested posi-
tive for the familial mutation, but no clinical information
is available.
Case 10 (III-1)
The five-year-old son of II-2 is reportedly being investi-
gated for possible HSCR. Family history and clinical
findings of all family members are summarized in
Figure 1 and Table 1, respectively.
Discussion
CCHS is a disease of the autonomic nervous system that
is not as rare as previously thought, with an estimated in-
cidence of one per 200,000 live births [1,3,7]. Classically,
it presents as sudden death in infancy because of a fail-
ure of autonomic control of ventilation during sleep
(Ondine curse) [1,2,5]. Infants with CCHS typically do
not breathe spontaneously for the first few months of life,
but can develop breathing patterns while awake over
time. The hypoventilation associated with CCHS is more
severe in non-rapid eye sleep, which contrasts with other
respiratory disorders [8]. Untreated, this may result in
pulmonary hypertension, cor pulmonale and central ner-
vous system hypoxic damage [1,5]. Other clinical mani-
festations of CCHS as a result of generalized autonomic
nervous system dysfunction include cardiac arrhythmias,
orthostatic hypotension, episodes of profuse diaphoresis,
pupillary abnormalities, severe constipation, HSCR and
neural crest tumors [1]. CCHS is diagnosed in newborns
as clinical symptoms develop in the absence of any
neuromuscular, cardiovascular or respiratory system ab-
normalities [1,3,5].
Late-onset CCHS (LO-CCHS) is diagnosed in adults
who present with signs of central alveolar hypoven-
tilation. They are at risk for polycythemia and pulmo-Table 1 Tabulation of clinical manifestations of individual fam
1 2 3
III-3 II-5 III-4 I
Pupillary abnormalities + + +
Obstructive sleep apnea - + -
Neonatal apneas/desaturations + ? +
Low resting O2 saturation levels - + -
Pulmonary hypertension - - -
Cardiac arrest - - -
Hirschsprung disease + - -
Constipation - - +
Episodic diaphoresis - + -
Neural crest tumors - - -
Present (+), Absent (−), (?) Unknown or not formally assessed.nary hypertension. Most adults with LO-CCHS carry a
smaller expansion in PHOX2B when compared with
infants with classic CCHS, but NPARMs have also occa-
sionally been reported [1,2,5,9].
HSCR is a developmental disorder of the enteric sys-
tem that is characterized by aganglionosis in the distal
colon causing bowel obstruction. It occurs in approxi-
mately one out of every 5000 live births [6]. It generally
presents as a failure to pass meconium as a neonate or,
later in childhood, as chronic constipation, abdominal
distension and emesis. Although HSCR can arise as an
isolated finding, it can also be an associated feature in
16% to 50% of cases of CCHS [1,4,6,7,10].
CCHS is an autosomal dominant disorder caused by
mutations in the PHOX2B gene on chromosome 4 [1,3].
This gene was originally identified in mice with abnor-
malities of the autonomic nervous system. Most cases
are associated with PARMs in exon three [1]. Normal in-
dividuals carry a 20-alanine repeat sequence, while those
with classic CCHS have expansions in the +5 to +13
range. Studies have demonstrated a direct correlation
between the repeat number and disease severity. Individ-
uals with small expansions (25 repeats) have LO-CCHS
and rarely require ventilation, while those with larger
expansions (27 to 33 repeats) often require continuous
ventilatory support [1,3-5]. Less common are the
NPARMs (frameshift and nonsense mutations) in
PHOX2B. These are commonly associated with a more
severe clinical phenotype including the need for continu-
ous ventilatory support, tumors of neural crest origin
and HSCR [1]. As with many autosomal dominant con-
ditions, CCHS demonstrates variable expressivity and
reduced penetrance. The family in our case was unusual
in that most family members were relatively mildly af-
fected and only identified later in childhood or as adults
after the diagnosis was made in the proband (III-3),ily members
Case
4 5 6 7 8 9 10
-1 II-4 II-3 III-2 IV-1 II-2 III-1
+ + + ? ? ? ?
+ + + - - ? ?
? ? ? ? + ? ?
- + - - + ? ?
- + - - - ? ?
+ - - - - ? ?
- - - - + ? ?+
+ - - + - ? ?
- - + - - ? ?
- - - - - ? ?
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with more severe disease. This again confirms the highly
variable clinical presentation for CCHS and the import-
ance of sleep studies in apparently asymptomatic family
members [11]. Phenotypic differences previously de-
scribed in monozygotic twins with CCHS suggest a role
for non-genetic factors in clinical variability and disease
severity [12]. Reduced penetrance and variable expressiv-
ity has also been described in LO-CCHS [9,13].
PHOX2B mutation carriers are at risk for chronic
hypoventilation and arrhythmias and must be assessed
and managed by specialists familiar with CCHS. The
American Thoracic Society has issued a clinical policy
statement on diagnosis and treatment of CCHS that is
largely based on expert opinion [1]. The primary goal of
treatment is to ensure optimal ventilation and oxygen-
ation through the use of mechanical assisted ventilation.
Most individuals require at least nocturnal ventilation
and some may need continuous ventilator support to
avoid the long-term complications of chronic hypox-
emia. In newborns and children, expert opinion recom-
mends positive pressure ventilation via tracheostomy. In
all cases, close monitoring is necessary to maintain
normal oxygen levels for various activities and to
minimize deleterious effects on cognitive development.
Sedatives and central nervous system depressants should
be avoided as they can depress ventilatory drive and, in
the absence of ventilatory support, can lead to death.
Individuals with CCHS can survive to adulthood with
appropriate management. The cause of death in individ-
uals with CCHS relates to suboptimal ventilation, the
use of substances that depress ventilatory control and
cardiac arrhythmias. Screening recommendations for
individuals with CCHS based on genotype are published
[1]. Presymptomatic and prenatal diagnostic testing
are available in instances where the disease-causing
PHOX2B mutation has been identified.Conclusions
In this report, we highlight the importance of consider-
ing CCHS in the differential diagnosis for HSCR or
when the medical or family histories are suggestive of
generalized autonomic nervous system dysregulation.
The clinical variability demonstrated by this family sug-
gests that CCHS is likely an unrecognized entity and
that previous frequency measurements are probably un-
derestimates. All clinicians must maintain a high index
of suspicion for CCHS in order to diagnose and manage
mildly symptomatic cases, to avoid the associated long-
term morbidity and mortality, and to permit genetic
testing and counseling for families. Multidisciplinary
involvement is necessary for appropriate treatment,
management and monitoring of individuals with CCHS.Consent
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